________________________________________________________________________________________________________________________________

(C) Wolf G Kroner 2010 - Ed Torres, Ely LillyIs that worth a dollar, or a million dollars?

December 2010. What strategies is Lilly’s Venture Fund pursuing in the US and Latin America. Ed Torres, Managing Director of Lilly Ventures Fund describes for B2Bioworld investment policies in biotechnology, medical technologies, and healthcare IT, as well as future plans. There will be a distinct change with regard to the Fund’s approach in Europe. But what is at stake, when non-profit organisations have a major say? What will be the critical input to the parent company in developing its global business and filling up the pipeline. Has that worked out today?

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 7 pages
- Includes overview of investments by Lilly Ventures as well as co-investors (as of Dec 2010)

Full Company License enquire here

Back to section

Related Editorial Articles

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Upcoming opportunities in the German M&A market

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Patenting Stem Cells – Behind the front Stages

Horizon Discovery: Mitigating risks and developing the U.S. business

The Myriad Way
Peter D Meldrum, CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Thermo Fisher’s BRIMS-Strategy Under Testing
Translating fishing expeditions into targeted assays

Roche Ethiopia: Build-up of an emerging market